USD 5.0
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 1.61 Billion | 1.21 Billion | 871.2 Million | 895.2 Million | 908.8 Million |
Cost of Revenue | 519 Million | 428.5 Million | 301 Million | 303.5 Million | 315.2 Million |
Gross Profit | 1.09 Billion | 787.8 Million | 570.2 Million | 591.7 Million | 593.6 Million |
Operating Expenses | 939.6 Million | 711.5 Million | 512.7 Million | 454.4 Million | 496.2 Million |
Selling, General and Administrative Expenses | 781.2 Million | 580.7 Million | 396.3 Million | 356 Million | 375.6 Million |
Research and Development Expenses | 260.39 Million | 138.4 Million | 117.3 Million | 108.6 Million | 121.3 Million |
Other Expenses | -101.99 Million | - | - | - | - |
Cost and Expenses | 1.45 Billion | 1.14 Billion | 813.7 Million | 757.9 Million | 811.4 Million |
Operating Income | 154.8 Million | 82.3 Million | 60 Million | 127.2 Million | 101 Million |
Interest Expense | 39.4 Million | 21.7 Million | 19.4 Million | 22.4 Million | 23.4 Million |
Income Tax Expense | 15 Million | 5.1 Million | 10.7 Million | -26.5 Million | 13.3 Million |
Earnings before Tax | 119 Million | 53.7 Million | 40.5 Million | 103.4 Million | 81 Million |
Net Income | 104.1 Million | 48.6 Million | 29.8 Million | 129.8 Million | 67.7 Million |
Earnings Per Share Basic | 0.98 | 0.46 | 0.30 | 1.30 | 0.68 |
Earnings Per Share Diluted | 0.98 | 0.46 | 0.30 | 1.30 | 0.68 |
Weighted Average Shares Outstanding | 106.22 Million | 104.85 Million | 100.49 Million | 99.8 Million | 99.8 Million |
Weighted Average Shares Outstanding (Diluted) | 106.55 Million | 105.39 Million | 100.49 Million | 99.8 Million | 99.8 Million |
Gross Margin | 0.68 | 0.65 | 0.65 | 0.66 | 0.65 |
EBIT Margin | 0.20 | 0.16 | 0.18 | 0.24 | 0.20 |
Profit Margin | 0.06 | 0.04 | 0.03 | 0.14 | 0.07 |
EBITDA | 320.6 Million | 198.8 Million | 154.9 Million | 213.5 Million | 184.2 Million |
Earnings Before Tax Margin | 0.10 | 0.07 | 0.07 | 0.14 | 0.11 |
Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
---|---|---|---|---|---|---|
Revenue | 482 Million | 476 Million | 429 Million | 1.61 Billion | 473 Million | 424 Million |
Cost of Revenue | 151 Million | 149 Million | 139 Million | 519 Million | 149 Million | 134 Million |
Gross Profit | 331 Million | 327 Million | 290 Million | 1.09 Billion | 324 Million | 290 Million |
Operating Expenses | 272 Million | 275 Million | 257 Million | 944 Million | 267 Million | 242 Million |
Selling, General and Administrative Expenses | 231 Million | 231 Million | 218 Million | - | 222 Million | 198 Million |
Research and Development Expenses | 39 Million | 45 Million | 43 Million | - | 45 Million | 44 Million |
Other Expenses | 2 Million | -2 Million | - | - | - | - |
Cost and Expenses | 423 Million | 424 Million | 396 Million | 1.46 Billion | 416 Million | 376 Million |
Operating Income | 61 Million | 53 Million | 32 Million | 150 Million | 57 Million | 48 Million |
Interest Expense | - | - | - | 39.9 Million | 8 Million | 8 Million |
Income Tax Expense | 6 Million | 5 Million | 5 Million | 15 Million | 4 Million | 6 Million |
Earnings before Tax | 51 Million | 41 Million | 16 Million | 119 Million | 49 Million | 41 Million |
Net Income | 45 Million | 36 Million | 11 Million | 104.1 Million | 45.1 Million | 35 Million |
Earnings Per Share Basic | 0.04 | 0.34 | 0.10 | - | 0.43 | 0.33 |
Earnings Per Share Diluted | 0.04 | 0.34 | 0.10 | - | 0.42 | 0.33 |
Weighted Average Shares Outstanding | 104.9 Million | 105.88 Million | 104.9 Million | 104.9 Million | 104.9 Million | 104.9 Million |
Weighted Average Shares Outstanding (Diluted) | 105.4 Million | 105.9 Million | 106.5 Million | 106.3 Million | 106.6 Million | 106.7 Million |
Gross Margin | 0.69 | 0.69 | 0.68 | 0.68 | 0.68 | 0.68 |
EBIT Margin | 0.23 | 0.21 | 0.18 | - | 0.16 | 0.21 |
Profit Margin | 0.09 | 0.08 | 0.03 | 0.06 | 0.10 | 0.08 |
EBITDA | 109 Million | 100 Million | 79 Million | - | 78 Million | 91 Million |
Earnings Before Tax Margin | 0.13 | 0.11 | 0.07 | 0.09 | 0.12 | 0.11 |
OKTA
MAXHEALTH
LTHIF
OX2
MERCURYEV
9103